Reference : Pharmaco-economie du diabete de type 2.
Scientific journals : Article
Human health sciences : Endocrinology, metabolism & nutrition
Pharmaco-economie du diabete de type 2.
[fr] Pharmaco-economics of type 2 diabetes
Scheen, André mailto [Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale >]
Lefebvre, Pierre [Centre Hospitalier Universitaire de Liège - CHU > > Diabétologie,nutrition, maladies métaboliques >]
Revue Médicale de Liège
CHU de Liège
Yes (verified by ORBi)
[en] Cost of Illness ; Costs and Cost Analysis ; Diabetes Mellitus, Type 2/diagnosis/drug therapy/economics/prevention & control ; Diabetic Angiopathies/economics/prevention & control ; Economics, Pharmaceutical ; Health Care Costs ; Humans ; Hypoglycemic Agents/economics/therapeutic use ; Primary Health Care ; Risk Factors ; Socioeconomic Factors
[en] Type 2 diabetes has long been considered as a benign disease, whereas it is in fact associated with an enormous socio-economic cost. The major part of the burden of diabetes results from the management of complications (both direct and indirect costs), rather than from the various components of the antihyperglycaemic treatment itself. Solutions include a better prevention of the disease, an earlier diagnosis among individuals at risk, and an optimized management of diabetes, particularly in primary care settings, in order to avoid or retard the development of severe micro- or macroangiopathic complications which are particularly expensive.

There is no file associated with this reference.

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.